|Protalix BioTherapeutics Inc -- USA Stock|| |
USD 0.59 0.0125 2.16%
Founder and Executive VP of RandD
Dr. Yoseph Shaaltiel, Ph.D., is Executive Vice President Research Development of the company. Dr. Shaaltiel founded Protalix Ltd. in 1993 and has served as our Executive Vice President, Research and Development since December 2006. Prior to establishing Protalix Ltd., from 1988 to 1993, Dr. Shaaltiel was a Research Associate at the MIGAL Technological Center. He also served as Deputy Head of the Biology Department of the Biological and Chemical Center of the Israeli Defense Forces and as a Biochemist at Makor Chemicals Ltd. Dr. Shaaltiel was a Postdoctoral Fellow at the University of California at Berkeley and at Rutgers University in New Jersey. He has coauthored over 40 articles and abstracts on plant biochemistry and holds several patents
Age: 62 Founder Since 2016 Ph.D
972 4 988 9488 http://www.protalix.com
Shaaltiel received his Ph.D. in Plant Biochemistry from the Weizmann Institute of Science, an M.Sc. in Biochemistry from the Hebrew University and a B.Sc. in Biology from the Ben Gurion University.
The company has Return on Asset of (29.42) %
which means that on every $100 spent on asset it lost $29.42. This is way below average. In the same way, it shows return on shareholders equity (ROE)
of (30.1) %
meaning that it generated no profit with money invested by stockholders.
The company has 56.49 M in debt with debt to equity (D/E) ratio of 6.63 . This implies that the company may be unable to create cash to meet all of its financial commitments. Protalix BioTherapeutics Inc has Current Ratio of 2.7 demonstrating that it is liquid and is capable to disburse its financial commitments when the payables are due.
Protalix BioTherapeutics, Inc., a biopharmaceutical company, focuses on the development and commercialization of recombinant therapeutic proteins based on its proprietary ProCellEx protein expression system in Israel and internationally. Protalix BioTherapeutics, Inc. was founded in 1993 and is based in Karmiel, Israel. Protalix BioTherapeutics operates under Biotechnology classification in USA and traded on American Stock Exchange. It employs 190 people.Protalix BioTherapeutics Inc (PLX) is traded on American Stock Exchange in USA. It is located in ISRAEL and employs 190 people. Protalix BioTherapeutics is listed under Pharmaceutical Products category by Fama And French industry classification.